Recent Quotes (30 days)

You have no recent quotes
chg | %

Kane Biotech Inc  

(Public, CVE:KNE)   Watch this stock  
Find more results for kne
0.0000 (0.00%)
May 22 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.04 - 0.04
52 week 0.03 - 0.12
Open 0.04
Vol / Avg. 120,000.00/445,310.00
Mkt cap 4.29M
P/E     -
Div/yield     -
EPS -0.02
Shares 107.02M
Beta 0.64
Inst. own     -

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -1834.71% -904.89%
Operating margin -1703.00% -906.91%
EBITD margin - -884.76%
Return on average assets -103.87% -65.67%
Return on average equity -187.24% -79.72%
CDP Score - -


Suite 162, 196 Innovation Drive
+1-204-4531301 (Phone)
+1-204-4747552 (Fax)

Website links


Kane Biotech Inc. (Kane) is a Canada-based company engaged in the development and commercialization of products that prevent and remove microbial biofilms. The Company’s technologies include DispersinB, Aledex, StrixNB and KBI Antibacterial Disinfectant (KBI). Kane’s technology for the wound care market is DispersinB. The Company has a number of DispersinB formulations in development, including formulations with antibiotics and the antibiofilm enzyme B-N-Acetylglucosaminidase. Kane has developed antibiofilm-antimicrobial formulations for both the veterinary and human markets. The Aledex is used in medical device coating market. The KBI contains antimicrobial-antibiofilm combination consists of Chlorhexidine (CHX) and Sodium Metaperiodate (SMP). The StrixNB is used for the oral care market.

Officers and directors

Philip Renaud Independent Chairman of the Board
Mark Ahrens-Townsend President, Chief Executive Officer
Mark Matthewson Chief Financial Officer
Arvind K. Joshi M.D. Director
Mark H. Nawacki Director
Sarah Prichard Director